Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642018 · ClinicalTrials.gov registry record · Phase 2
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT00642018 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 154 participants.
The verdict
NCT00642018, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
Interventions
- DRUG Prednisone
- DRUG docetaxel
- DRUG LY2181308 sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642018
The ClinicalTrials.gov registry entry for NCT00642018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT00642018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642018 about?
NCT00642018 is a clinical study titled "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
What is the current status of trial NCT00642018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2008-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00642018?
The interventions under investigation include: Prednisone (DRUG), docetaxel (DRUG), LY2181308 sodium (DRUG).
Who is sponsoring clinical trial NCT00642018?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.